Sales of ALK inhibitors for non-small cell lung cancer in the US, Japan, and five major EU markets, by brand
($m), 2014-23

Brand..........2014...2015...2016...2017...2018...2019...2020...2021...2022...2023...CAGR 2014-23

Xalkori...........343.....338.....350.....360.....362.....329.....319.....307.....295.....282....-2.1%
Alecensa........14.......44.......50.......67.......81.......156.....192.....229.....254.....276.....39.7%
Zykadia..........30.......64.......84.......88.......95.......145......171.....195.....216.....236.....26.0%
brigatinib........0.........0.........0.........6.........28........37........47........57........67........72........n/a

Total............386......446......484.....521.....565.....667.....729.....788.....833.....866.....9.4%

Note: totals may not sum due to rounding.
CAGR = compound annual growth rate